Association between Mycobacterium tuberculosis Complex Phylogenetic Lineage and Acquired Drug Resistance

Courtney M. Yuen, Ekaterina V. Kurbatova*, Eleanor S. Click, J. Sean Cavanaugh, J. Peter Cegielski

Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Background: Development of resistance to antituberculosis drugs during treatment (i.e., acquired resistance) can lead to emergence of resistant strains and consequent poor clinical outcomes. However, it is unknown whether Mycobacterium tuberculosis complex species and lineage affects the likelihood of acquired resistance.

Methods: We analyzed data from the U.S. National Tuberculosis Surveillance System and National Tuberculosis Genotyping Service for tuberculosis cases during 2004–2011 with assigned species and lineage and both initial and final drug susceptibility test results. We determined univariate associations between species and lineage of Mycobacterium tuberculosis complex bacteria and acquired resistance to isoniazid, rifamycins, fluoroquinolones, and second-line injectables. We used Poisson regression with backward elimination to generate multivariable models for acquired resistance to isoniazid and rifamycins.

Results: M. bovis was independently associated with acquired resistance to isoniazid (adjusted prevalence ratio = 8.46, 95% CI 2.96–24.14) adjusting for HIV status, and with acquired resistance to rifamycins (adjusted prevalence ratio = 4.53, 95% CI 1.29–15.90) adjusting for homelessness, HIV status, initial resistance to isoniazid, site of disease, and administration of therapy. East Asian lineage was associated with acquired resistance to fluoroquinolones (prevalence ratio = 6.10, 95% CI 1.56–23.83).

Conclusions: We found an association between mycobacterial species and lineage and acquired drug resistance using U.S. surveillance data. Prospective clinical studies are needed to determine the clinical significance of these findings, including whether rapid genotyping of isolates at the outset of treatment may benefit patient management.

Introduction

The development of resistance to antituberculosis drugs during treatment, known as acquired resistance, can lead to the emergence of resistant strains and consequent poor clinical outcomes [1–3]. Acquired resistance is associated with improper use of antibiotics, inadequate regimens, or incomplete treatment [4–6]. However, it is not known if genetic bacterial strain differences are associated with the likelihood of acquired resistance.

The Mycobacterium tuberculosis complex (MTBC) comprises several species, of which M. tuberculosis, M. bovis, and M. africanum are most commonly associated with tuberculosis in humans. Of these, M. bovis is unique in that it is intrinsically resistant to pyrazinamide, one of the first-line drugs used to treat tuberculosis [7]. Four main phylogenetic lineages of M. tuberculosis (Indo-Oceanic, East Asian, East African-Indian, and Euro-American) and two lineages of M. africanum (West African 1 and 2) have been identified [8]. Studies from a variety of settings have reported associations between East Asian lineage or its dominant member, the Beijing genotype, and drug resistance [9–13]. However, these epidemiologic studies have not looked specifically at acquired resistance documented by repeated drug susceptibility testing during the course of tuberculosis treatment. Thus, these associations may reflect an increased risk of being infected with a strain that is already drug-resistant rather than an increased risk of developing resistance during treatment.

Because of the clinical and public health implications of developing resistance during treatment, we sought to determine whether MTBC species or lineage was associated with acquired resistance to four major classes of antituberculosis drugs using data from the U.S. National Tuberculosis Surveillance System (NTSS) and National Tuberculosis Genotyping Service (NTGS).
Methods

Case Inclusion

We analyzed NTSS data for new (i.e., occurring in a patient without prior history of tuberculosis) tuberculosis cases with baseline positive cultures from the 50 states and the District of Columbia during 2004–2011 for which a species or lineage was assigned, and for which drug susceptibility test (DST) results were available. NTSS collects sociodemographic and clinical information, including DST results, on all tuberculosis cases in the United States. DSTs for first-line drugs on the initial positive culture are routine in the United States, but repeated DSTs and DSTs on second-line drugs are performed only when indicated. DST results for the first isolate tested (i.e., initial DST results) are reported to NTSS; if repeated DST is performed, results for the last isolate on which DST was performed (i.e., final DST results) are reported to NTSS. Since 2004, NTGS has routinely performed genotyping on culture-positive cases and assigned lineage based on spoligotype and 12-locus mycobacterial interspersed repetitive unit variable number of tandem repeat [14]. The rules used for classification of lineage have been shown produce results consistent with lineage assignment based on long-sequence polymorphisms [14–16]. Data from NTGS and NTSS were linked to identify cases with assigned lineage.

We analyzed cases with and without acquired resistance to isoniazid, rifamycins (rifampin, rifabutin, and rifapentine), second-

![Figure 1. Selection of cases included in analysis. Abbreviations: TB = tuberculosis, DST = drug susceptibility test, AR = acquired resistance. doi:10.1371/journal.pone.0083006.g001](image-url)
line injectables (amikacin, kanamycin, and capreomycin, referred to collectively from here as “injectables”), and fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and drugs classified as “other quinolone” in NTSS). For each drug class, we restricted analysis to cases with initial susceptibility to all tested members of the class and a final DST result for at least one member. Acquired resistance to a drug was defined as resistance at the final DST to a drug to which the case’s first isolate had been susceptible at the initial DST. Acquired resistance to a drug class was defined as acquired resistance to any of the drugs in the class. No acquired resistance to a drug was defined as susceptibility at final DST to that drug at both initial and final DST. No acquired resistance to a drug class was defined as susceptibility at final DST to all tested members of the class.

**Statistical Analysis**

We determined characteristics associated with acquired resistance to isoniazid, rifamycins, injectables, and fluoroquinolones by calculating prevalence ratios (PR) with 95% confidence intervals (CI). A 95% CI excluding the null value (i.e., PR = 1.0) was considered statistically significant. We used multivariable Poisson regression to assess factors independently associated with acquired resistance to isoniazid and rifamycins. The initial multivariable model included species and lineage as well as variables with P<0.10 in univariate analysis and potential confounders based on biological plausibility or known epidemiologic association. We assessed confounding in the initial model and used backward elimination to determine variables included in the final model to obtain better precision around point estimates. To test the robustness of the multivariable model, we carried out sensitivity analyses using subsets of included cases. In one analysis, we included only cases caused by *M. tuberculosis* (i.e., excluding those caused by *M. bovis* and *M. africanum*); in another, we included only cases with initial susceptibility to isoniazid, rifampin, and ethambutol. We did not perform multivariable analysis for injectables and fluoroquinolones because of the small number of cases with documented acquired resistance to these drug classes. All statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).

### Table 1. Associations between *M. tuberculosis* complex lineage and acquired resistance to isoniazid, rifamycins, second-line injectables, and fluoroquinolones.

| Species, lineage       | Acquired resistance to isoniazid | Acquired resistance to rifamycins | Acquired resistance to injectables | Acquired resistance to fluoroquinolones |
|------------------------|----------------------------------|-----------------------------------|-----------------------------------|----------------------------------------|
|                        | Crude prevalence ratio (95% CI)  | Adjusted* prevalence ratio (95%CI) | Crude prevalence ratio (95% CI)  | Adjusted* prevalence ratio (95%CI)    | Crude prevalence ratio (95% CI)  | Crude prevalence ratio (95% CI) |
| *M. africanum*         |                                  |                                   |                                   |                                        |                                   |                                   |
| *M. bovis*             | 7.03 (2.66–18.56)                | 8.46 (2.96–24.14)                 | 6.61 (2.12–20.65)                 | 4.53 (1.29–15.90)                     |                                   |                                   |
| *M. tuberculosis*, East African-Indian | 0.46 (0.06–3.33)                | 0.48 (0.07–3.49)                 | 0.56 (0.08–4.05)                  | 1.09 (0.14–8.19)                     | 3.64 (0.42–31.27)                |                                   |
| *M. tuberculosis*, East Asian | 1.06 (0.52–2.15)                | 1.10 (0.45–2.90)                 | 1.31 (0.63–2.72)                  | 1.84 (0.86–3.93)                     | 2.59 (0.59–11.38)                | 6.10 (1.56–23.83)                |
| *M. tuberculosis*, Euro-American | Reference                      | Reference                         | Reference                         | Reference                             | Reference                         | Reference                         |
| *M. tuberculosis*, Indo-Oceanic | 1.02 (0.41–2.56)                | 1.14 (0.45–2.90)                 | 0.94 (0.34–2.65)                  | 1.46 (0.49–4.31)                     |                                   |                                   |

*Adjusted for HIV status.

1. Adjusted for homelessness, HIV status, initial resistance to isoniazid, site of disease, and administration of therapy.

Abbreviations: CI = confidence interval, ~ = no prevalence ratio calculated because no cases had acquired resistance.

doi:10.1371/journal.pone.0083006.t001

**Ethics Statement and Public Availability of Data**

All data were collected and analyzed as part of routine public health surveillance. The project was therefore determined not to be human subjects research by the U.S. Centers for Disease Control and Prevention (CDC) and did not require approval by an institutional review board.

Researchers may apply to analyze NTSS and NTGS data at CDC headquarters according to established procedures. In addition, a publicly available version of NTSS data is available at https://wonder.cdc.gov/ib.html.

**Results**

Among 105,400 tuberculosis cases counted by NTSS during 2004–2011, 51,223 (48.6%) met our inclusion criteria (Figure 1). Among this subset of cases, initial DST for isoniazid and at least one rifamycin were almost universal (>99%). In contrast, 6,258 (12.2%) and 4,742 (9.3%) had an initial DST result for at least one injectable or fluoroquinolone, respectively. For all four drug classes, the majority of cases (>90%) with initial DST results showed susceptibility at final DST. For all four drug classes, approximately 8% of cases initially susceptible to the drug class had a final DST result. Out of cases with final DST results, the proportion of cases with acquired resistance ranged from 1.2% for rifamycins to 2.5% for fluoroquinolones.

Species and phylogenetic lineage was associated with acquired resistance to isoniazid, rifamycins, injectables, and fluoroquinolones (Table 1). Because the numbers of cases with final DST results for injectables and fluoroquinolones was small, we calculated only crude PRs for these drug classes. *M. bovis* was associated with acquired resistance to both isoniazid (adjusted prevalence ratio [aPR] = 8.46, 95% CI 2.96–24.14) and rifamycins (aPR = 4.53, 95% CI 1.29–15.90). East Asian lineage was associated with acquired resistance to fluoroquinolones (PR = 6.10, 95% CI 1.56–23.83).

Sociodemographic and clinical factors showed no statistically significant associations with acquired resistance to isoniazid (Table 2). In contrast, acquired resistance to rifamycins was associated with older age groups (45–64 and ≥65 years), homelessness, injecting drug use, HIV infection, initial resistance to isoniazid, initial resistance to ethambutol, combined pulmonary...
| Species, lineage          | Included cases | Acquired resistance n (% of included) | Crude PR (95% CI) |
|---------------------------|----------------|---------------------------------------|------------------|
| *M. africanum*            | 16             | 0 (0.0)                               | –                |
| *M. bovis*                | 36             | 4 (11.1)                              | 7.03 (2.66–18.56)|
| *M. tuberculosis*         | 364            | 42 (1.6)                              | Reference        |
| *M. tuberculosis*, East African-Indian | 137       | 1 (0.7)                               | 0.46 (0.06–3.33) |
| *M. tuberculosis*, East Asian | 541      | 9 (1.7)                               | 1.05 (0.52–2.15) |
| *M. tuberculosis*, Euro-American | 2,656  | 42 (1.6)                              | Reference        |
| *M. tuberculosis*, Indo-Oceanic | 310       | 5 (1.6)                               | 1.02 (0.41–2.56) |
| Sex                       |                |                                       |                  |
| Female                    | 1,068          | 23 (1.7)                              | 1.03 (0.60–1.78) |
| Male                      | 2,628          | 51 (1.6)                              | Reference        |
| Age                       |                |                                       |                  |
| 0–24                      | 363            | 6 (1.4)                               | 0.80 (0.31–2.11) |
| 25–44                     | 1,284          | 28 (1.7)                              | Reference        |
| ≥65                       | 642            | 10 (1.6)                              | 0.64 (0.27–1.48) |
| Race and ethnicity        |                |                                       |                  |
| Hispanic                  | 1,123          | 24 (1.9)                              | 1.18 (0.59–2.34) |
| American Indian           | 28             | 1 (0.6)                               | 2.25 (0.30–16.58)|
| Asian                     | 643            | 9 (1.4)                               | 0.78 (0.33–1.88) |
| Non-Hispanic Black        | 1,063          | 18 (1.7)                              | 1.07 (0.53–2.34) |
| Non-Hispanic White        | 818            | 13 (1.6)                              | Reference        |
| Country of birth          |                |                                       |                  |
| Foreign-born              | 1,864          | 32 (1.7)                              | 0.91 (0.58–1.42) |
| U.S.-born                 | 1,829          | 29 (1.6)                              | Reference        |
| Region of birth*          |                |                                       |                  |
| Africa                    | 188            | 1 (0.5)                               | 0.34 (0.05–2.45) |
| Americas (other than United States) | 919    | 20 (2.2)                             | 1.37 (0.78–2.41) |
| Eastern Mediterranean     | 51             | 1 (0.2)                               | 1.24 (0.17–8.90) |
| Europe                    | 74             | 2 (0.7)                               | 1.70 (0.41–7.01) |
| South-East Asia           | 169            | 2 (1.2)                               | 0.75 (0.18–3.10) |
| Western Pacific           | 458            | 6 (1.3)                               | 0.83 (0.35–1.98) |
| United States             | 1,829          | 29 (1.6)                              | Reference        |
| In correctional facility at diagnosis | 133   | 2 (1.5)                               | 0.91 (0.22–3.67) |
| Homeless                  |                |                                       |                  |
| Yes                       | 353            | 2 (0.6)                               | 0.32 (0.08–1.30) |
| No                        | 3,328          | 59 (1.8)                              | Reference        |
| Injecting drug use        |                |                                       |                  |
| Yes                       | 97             | 2 (2.1)                               | 1.25 (0.31–5.04) |
| No                        | 3,572          | 59 (1.7)                              | Reference        |
| Non-injecting drug use    |                |                                       |                  |
| Yes                       | 430            | 8 (1.9)                               | 1.14 (0.44–1.90) |
| No                        | 3,235          | 53 (1.6)                              | Reference        |
| Excess alcohol use        |                |                                       |                  |
| Yes                       | 870            | 10 (1.1)                              | 0.73 (0.54–2.37) |
| No                        | 2,804          | 51 (1.8)                              | Reference        |
| HIV status                |                |                                       |                  |
| Positive                  | 257            | 4 (1.6)                               | 0.81 (0.29–2.23) |
| Negative                  | 2,497          | 48 (1.9)                              | Reference        |
| Unknown                   | 942            | 9 (1.0)                               | 0.50 (0.24–1.01) |
| Initial DST result for rifamycins | 20   | 1 (5.0)                              | 3.06 (0.45–21.01)|
| Susceptible to all tested | 3,672          | 60 (1.6)                              | Reference        |
| Initial DST result for pyrazinamide | 68  | 2 (2.9)                              | 1.98 (0.49–8.01) |
| Susceptible               | 2,619          | 39 (1.5)                              | Reference        |
| Initial DST result for ethambutol | 8   | 0 (0.0)                              | –                |
| Susceptible               | 3,681          | 60 (1.6)                              | Reference        |
| Initial chest radiograph  |                |                                       |                  |
| Abnormal                  | 3,440          | 55 (1.6)                              | 0.78 (0.29–2.14) |
| Normal                    | 196            | 4 (2.0)                               | Reference        |
| Cavity seen on chest radiograph | 1,598 | 27 (1.7)                             | 1.07 (0.64–1.79) |
similar results. The association between isoniazid, rifampin, and ethambutol (data not shown). Analysis of restricting cases to those with documented initial susceptibility to pyrazinamide DST results.

In multivariable analysis, acquired resistance to isoniazid was independently associated with *M. bovis* and with unknown HIV status (aPR = 0.46, 95% CI 0.23–0.95) (Table 4). Acquired resistance to rifamycins was associated with *M. bovis*, homelessness (aPR = 2.21, 95% CI 1.08–4.52), HIV infection (aPR = 8.39, 95% CI 4.43–17.85), initial resistance to isoniazid (aPR = 10.37, 95% CI 5.65–19.00), extrapulmonary site of disease (aPR = 2.31, 95% CI 1.17–4.58), and self-administered therapy (aPR = 2.52, 95% CI 1.01–6.30) (Table 4).

We repeated univariate and multivariable analyses restricting cases to those caused by *M. tuberculosis* (data not shown). Similar associations with independent predictors other than *M. bovis* were observed for both acquired resistance to isoniazid and acquired resistance to rifamycins.

We also repeated univariate and multivariable analyses restricting cases to those with documented initial susceptibility to isoniazid, rifampin, and ethambutol (data not shown). Analysis of predictors associated with acquired resistance to isoniazid gave similar results. The association between *M. bovis* and acquired resistance to rifamycins lost statistical significance (aPR = 3.83, 95% CI 0.99–14.79), but independent associations with homelessness, HIV infection, and extrapulmonary site of disease were once again observed. We did not repeat analyses restricting cases to those with documented initial susceptibility to pyrazinamide because almost all *M. bovis* cases would have been excluded from analysis, as well as a substantial portion of other cases that lacked pyrazinamide DST results.

**Discussion**

This large study among tuberculosis cases with repeated DST results suggests an association between species and lineage of MTBC bacteria and acquired resistance to antituberculosis drugs. We found *M. bovis* to be associated with acquired resistance to both isoniazid and rifamycins, and these associations were independent of other predictors of acquired resistance such as initial resistance to another first-line drug and HIV infection. In addition, our results suggest an association between East Asian lineage and acquired resistance to fluoroquinolones, although the number of cases analyzed was too small to support multivariable analysis to identify potential confounders.

The association between *M. bovis* and acquired resistance to both isoniazid and rifamycins may be partly attributable to its inherent resistance to pyrazinamide, a drug included in standard four-drug regimens used to treat drug-susceptible tuberculosis [17] because of its sterilizing properties and its ability to kill dormant, non-replicating bacilli [18,19]. However, our results suggest that resistance to pyrazinamide may not entirely explain the association between *M. bovis* and acquired resistance, as initial resistance to pyrazinamide did not predict acquired resistance to isoniazid or rifampin in our analysis. Issues with false positivity associated with standard methods for testing pyrazinamide susceptibility [20,21] may have contributed to this lack of an association. However, only about half of the cases included in our analyses that had initial resistance to pyrazinamide were caused by *M. bovis*, and when *M. bovis* cases were excluded from analysis, no association was observed between resistance to pyrazinamide at initial DST and acquired resistance to either isoniazid or rifamycins. These results suggest that *M. bovis* may have attributes other than resistance to pyrazinamide that increase the likelihood of its acquiring resistance to other drugs.

The finding that East Asian lineage is associated with acquired resistance to fluoroquinolones is consistent with the numerous studies reporting associations between East Asian lineage or the Beijing genotype with drug resistance [9–13]. Furthermore, an association between the Beijing genotype and primary fluoroquinolone resistance has been reported [22]. A potential biological mechanism that could explain associations between this lineage and both initial and acquired drug resistance has been suggested by *in vitro* studies reporting that East Asian strains have an elevated basal mutation rate compared to East African-Indian and Euro-American strains [23,24], and are therefore more likely to develop mutations leading to drug resistance. Finally, our observation that acquired resistance to fluoroquinolones was associated with East Asian lineage but not to region of origin suggests that the observed association is not attributable to host factors among persons from regions where the East Asian lineage is common [8].

Our observation that initial resistance to isoniazid is associated with acquired resistance to rifamycins is consistent with other studies that have shown initial resistance to one or more drugs to be a strong risk factor for additional acquired resistance [25]. Surprisingly, we did not observe strong evidence for an association between initial resistance to rifamycins and acquired resistance to isoniazid. The lack of association could be attributable to the small

### Table 2. Cont.

| Included cases | Acquired resistance n (% of included) | Crude PR (95% CI) |
|----------------|-------------------------------------|------------------|
| Sputum microscopy result for AFB | No 1,972 31 (1.6) Reference | |
| Positive | 2,764 44 (1.6) 0.83 (0.46–1.48) | |
| Negative | 778 15 (1.9) Reference | |
| Site of disease | Extrapulmonary only 179 1 (0.6) 0.35 (0.05–2.53) | |
| Pulmonary only | 364 10 (2.7) 1.73 (0.89–3.39) | |
| Pulmonary and extrapulmonary site of disease | 3,152 50 (1.6) Reference | |
| Administration of therapy | DOT only 2,232 38 (1.7) Reference | |
| Self-administered and DOT | 1,216 18 (1.5) 0.87 (0.50–1.52) | |
| Self-administered only | 199 1 (0.5) 0.30 (0.04–2.14) | |

*Regions defined by World Health Organization [37]. Missing values not reported in table. Abbreviations: PR = prevalence ratio, CI = confidence interval, DST = drug susceptibility test, AFB = acid-fast bacilli, DOT = directly observed therapy. doi:10.1371/journal.pone.0083006.t002
| Species, lineage                        | Included cases | Acquired resistance n (% of included) | Crude PR (95% CI) |
|----------------------------------------|----------------|--------------------------------------|------------------|
| *M. africanum*                         | 19             | 0 (0.0)                              | –                |
| *M. bovis*                             | 39             | 3 (7.7)                              | 6.61 (2.12–20.65) |
| *M. tuberculosis,* East African-Indian | 154            | 1 (0.6)                              | 0.56 (0.08–4.05) |
| *M. tuberculosis,* East Asian           | 590            | 9 (1.5)                              | 1.31 (0.63–2.72) |
| *M. tuberculosis,* Euro-American        | 2,836          | 33 (1.2)                             | Reference        |
| *M. tuberculosis,* Indo-Oceanic         | 364            | 4 (1.1)                              | 0.94 (0.34–2.65) |
| Sex                                    |                |                                      |                  |
| Female                                 | 1,161          | 13 (1.1)                             | 0.86 (0.46–1.61) |
| Male                                   | 2,841          | 37 (1.3)                             | Reference        |
| Age                                    |                |                                      |                  |
| 0–24                                   | 399            | 3 (0.8)                              | 0.35 (0.11–1.14) |
| 25–44                                  | 1,399          | 30 (2.2)                             | Reference        |
| ≥65                                    | 673            | 2 (0.3)                              | 0.14 (0.03–0.58) |
| Race and ethnicity                     |                |                                      |                  |
| Hispanic                               | 1,222          | 17 (1.4)                             | 1.72 (0.72–4.12) |
| American Indian                        | 30             | 0 (0.0)                              | –                |
| Asian                                  | 748            | 8 (1.1)                              | 1.32 (0.48–3.62) |
| Non-Hispanic Black                     | 1,113          | 18 (1.6)                             | 2.00 (0.84–4.76) |
| Non-Hispanic White                     | 864            | 7 (0.8)                              | Reference        |
| Country of birth                       |                |                                      |                  |
| Foreign-born                           | 2,067          | 24 (1.2)                             | 0.86 (0.50–1.50) |
| U.S.-born                              | 1,932          | 26 (1.3)                             | Reference        |
| Region of birth*                       |                |                                      |                  |
| Africa                                 | 204            | 3 (1.5)                              | 1.09 (0.33–3.58) |
| Americas (other than United States)    | 993            | 12 (1.2)                             | 0.90 (0.46–1.77) |
| Eastern Mediterranean                  | 58             | 1 (1.7)                              | 1.28 (0.18–9.28) |
| Europe                                 | 78             | 0 (0.0)                              | –                |
| South-East Asia                        | 191            | 2 (1.0)                              | 0.78 (0.19–3.25) |
| Western Pacific                        | 538            | 6 (1.1)                              | 0.83 (0.34–2.00) |
| United States                          | 1,932          | 26 (1.3)                             | Reference        |
| In correctional facility at diagnosis  |                |                                      |                  |
| Yes                                    | 150            | 4 (2.7)                              | 2.23 (0.81–6.11) |
| No                                     | 3,847          | 39 (1.2)                             | Reference        |
| Homeless                               |                |                                      |                  |
| Yes                                    | 372            | 11 (3.0)                             | 2.74 (1.42–5.30) |
| No                                     | 3,613          | 39 (1.1)                             | Reference        |
| Injecting drug use                     |                |                                      |                  |
| Yes                                    | 105            | 5 (4.8)                              | 4.09 (1.66–10.10) |
| No                                     | 3,867          | 45 (1.2)                             | Reference        |
| Non-injecting drug use                 |                |                                      |                  |
| Yes                                    | 460            | 7 (1.5)                              | 1.24 (0.56–2.74) |
| No                                     | 3,508          | 43 (1.2)                             | Reference        |
| Excess alcohol use                     |                |                                      |                  |
| Yes                                    | 933            | 14 (1.5)                             | 1.27 (0.69–2.34) |
| No                                     | 3,045          | 36 (1.2)                             | Reference        |
| HIV status                             |                |                                      |                  |
| Positive                               | 275            | 24 (8.7)                             | 12.46 (6.91–22.45) |
| Negative                               | 2,712          | 19 (0.7)                             | Reference        |
| Unknown                                | 1,015          | 7 (0.7)                              | 0.98 (0.42–2.23) |
| Initial DST result for isoniazid       |                |                                      |                  |
| Resistant                              | 328            | 20 (6.1)                             | 7.45 (4.28–12.98) |
| Susceptible                            | 3,667          | 30 (0.8)                             | Reference        |
| Initial DST result for pyrazinamide    |                |                                      |                  |
| Resistant                              | 84             | 2 (2.4)                              | 1.76 (0.43–7.16) |
| Susceptible                            | 2,878          | 39 (1.4)                             | Reference        |
| Initial DST result for ethambutol      |                |                                      |                  |
| Resistant                              | 39             | 2 (5.1)                              | 4.22 (1.06–16.76) |
| Susceptible                            | 3,952          | 48 (1.2)                             | Reference        |
| Initial chest radiograph               |                |                                      |                  |
| Abnormal                               | 3,715          | 46 (1.2)                             | 0.69 (0.25–1.91) |
| Normal                                 | 224            | 4 (1.8)                              | Reference        |
| Cavity seen on chest radiograph        |                |                                      |                  |
| Yes                                    | 1,731          | 16 (0.9)                             | 0.58 (0.32–1.05) |
| No                                     | 2,136          | 34 (1.6)                             | Reference        |
number of cases with initial rifamycin resistance in the absence of initial isoniazid resistance. Out of 3,692 cases with initial susceptibility to isoniazid and a documented initial DST result for at least one rifamycin, only 20 (0.5%) were resistant to rifamycins. In contrast, 328 (8.2%) of the 3,995 cases with initial susceptibility to rifamycins and a documented initial DST result for isoniazid were resistant to isoniazid.

The association between HIV infection and acquired resistance to rifamycins may be attributable to interactions between rifamycins and antiretroviral drugs used to treat HIV [26], and is consistent with previous studies that observed acquired resistance to both rifampin and rifapentine in patients being treated for TB-HIV [27,28]. However, we could not test this hypothesis as NTSS does not collect information on antiretroviral therapy. The basis of the negative association between unknown HIV status and acquired resistance to isoniazid is unknown, but may reflect an association not with HIV status but with particular tuberculosis control programs that did not report HIV status of patients during the time period of this analysis [29].

Finally, we observed an independent association between self-administered therapy and acquired resistance to rifamycins, reinforcing the rationale behind using directly observed therapy (DOT) to promote completion of treatment and discourage acquisition of drug resistance [17,30]. This contrasts with results

| Included cases | Acquired resistance n (% of included) | Crude PR (95% CI) |
|----------------|--------------------------------------|------------------|
| **Sputum microscopy result for AFB** | | |
| Positive | 2,976 | 40 (1.3) | 1.15 (0.58–2.29) |
| Negative | 854 | 10 (1.2) | Reference |
| **Site of disease** | | |
| Extrapulmonary only | 203 | 1 (0.5) | 0.53 (0.07–3.82) |
| Pulmonary and extrapulmonary | 386 | 17 (4.4) | **4.70** (2.63–8.38) |
| Pulmonary only | 3,412 | 32 (0.9) | Reference |
| **Administration of therapy** | | |
| DOT | 2,418 | 29 (1.2) | Reference |
| Self-administered and DOT | 1,322 | 13 (1.0) | 0.82 (0.43–1.57) |
| Self-administered only | 210 | 6 (2.9) | **2.38** (1.00–5.67) |

*Regions defined by World Health Organization [37]. Missing values not reported in table.

Abbreviations: PR = prevalence ratio, CI = confidence interval, DST = drug susceptibility test, AFB = acid-fast bacilli, DOT = directly observed therapy.

doi:10.1371/journal.pone.0083006.t003

Table 4. Independent predictors of acquired resistance to isoniazid and rifamycins in multivariable regression analysis.

| Species, lineage | Adjusted prevalence ratio for acquired resistance to isoniazid (95% CI) | Adjusted prevalence ratio for acquired resistance to rifamycins (95% CI) |
|------------------|-------------------------------------------------|-------------------------------------------------|
| M. bovis | 8.46 (2.96–24.14) | 4.53 (1.29–15.90) |
| M. tuberculosis, East African Indian | 0.48 (0.07–3.49) | 1.09 (0.14–8.19) |
| M. tuberculosis, East Asian | 1.10 (0.53–2.25) | 1.84 (0.86–3.93) |
| M. tuberculosis, Euro American | Reference | Reference |
| M. tuberculosis, Indo Oceanic | 1.14 (0.45–2.90) | 1.46 (0.49–4.31) |
| Homeless | Yes | Not included in model | **2.21** (1.08–4.52) |
| No | Reference | Reference |
| HIV status | Positive | 0.67 (0.24–1.89) | **8.89** (4.43–17.85) |
| Negative | Reference | Reference |
| Unknown | 0.46 (0.23–0.95) | 0.75 (0.29–1.94) |
| Initial DST result for isoniazid | Resistant | Not included in model | **10.37** (5.65–19.00) |
| Susceptible | Reference | Reference |
| Site of disease | Extrapulmonary only | Not included in model | **2.31** (1.17–4.58) |
| Pulmonary and extrapulmonary | 0.44 (0.06–3.28) | Reference |
| Pulmonary only | Reference | Reference |
| Administration of therapy | DOT only | Not included in model | Reference |
| Self-administered and DOT | 0.84 (0.44–1.63) | Reference |
| Self-administered only | **2.52** (1.01–6.30) | Reference |

Abbreviation: CI = confidence interval, DST = drug susceptibility test, DOT = directly observed therapy.

doi:10.1371/journal.pone.0083006.t004
of a recent meta-analysis of prospective observational studies and controlled trials, which found no statistically significant pooled risk difference for DOT versus self-administered therapy based on two included studies reporting acquired drug resistance as an outcome [31]. In their discussion, the authors suggest that retrospective studies reporting an association between poor treatment outcomes and self-administered therapy as compared to DOT have typically been unable to distinguish between the effect of direct observation itself and that of the programmatic improvements that accompanied the establishment of DOT as the standard of care. We believe our findings do not reflect this limitation because the current U.S. national TB elimination strategy, including DOT, was implemented during the 1990s, and important programmatic improvements are not likely to have been major factors during 2004–2011.

Our study was subject to several important limitations. First, initial DST for first-line drugs is routine, but repeated DST is discretionary in the United States. Therefore, the cases included in our analysis represented a small proportion of genotyped tuberculosis cases in NTSS, and are not representative of the general tuberculosis patient population in the United States. Because clinicians are more likely to repeat DSTs for patients because of clinical indications such as apparent ineffective treatment, the prevalence of acquired resistance among cases included in our analysis likely overestimates the prevalence in the general tuberculosis patient population. Furthermore, because DST for second-line drugs is also discretionary, very few genotyped cases had both initial and final DST results for injectables and fluoroquinolones. The small number of cases with acquired resistance to these two drug classes prevented us from analyzing the association between acquired resistance and M. bovis, and may have contributed to the lack of an observed association between lineage and acquired resistance to injectables. In addition, because of the small number of cases, we were unable to perform multivariable analyses, although clinical and sociodemographic factors associated with acquired resistance to both injectables and fluoroquinolones have previously been reported [32]. Finally, the small number of cases with acquired resistance to any drug may make overinterpretation of results possible.

Our study was also limited by the data available through NTSS and NTGS. Because only DST results for the first and last isolate tested are reported to NTSS, we could not include time to acquisition of drug resistance in our analysis. In addition, we could not include treatment regimen in our analysis because only the drugs in the initial regimen are reported to NTSS. Finally, while drug availability in individual patients may influence risk of acquired resistance [33], no data on serum drug concentrations or other pharmacokinetic measurements were available in NTSS that would enable us to consider this factor in our analysis.

Based on the data available in NTGS, we did not have genotyping results for both initial and final isolates and therefore could not confirm that the same strain was tested at initial and final DSTs. It is therefore possible that some cases were misclassified as having acquired resistance when in fact the change in DST result was attributable to a mixed-strain infection or re-infection during treatment, although the risk for either is generally thought to be low in low-incidence settings such as the United States [34,35]. In addition, although NTGS has been performing routine genotyping on culture-positive cases since 2004, not all states started utilizing the service comprehensively at the same time, and the proportion of culture-positive cases with available genotypes ranged from 52% in 2004 to 89% in 2010. Because some states selectively genotyped cases in earlier years, cases with certain characteristics, such as being associated with outbreaks, may be overrepresented in our sample.

In conclusion, among patients reported in the U.S. surveillance system with both initial and final DST results, M. bovis was independently associated with acquired resistance to isoniazid and rifampicins, and East Asian lineage may be associated with acquired resistance to fluoroquinolones. These results suggest that knowledge of risk factors for M. bovis infection such as Hispanic ethnicity, age <15 years, and extrapulmonary disease [36] may be useful for identifying patients with increased risk for acquired isoniazid and rifampicin resistance. In addition, patients from countries in East and Southeast Asia, where the East Asian lineage is common, may be at increased risk for acquired resistance to fluoroquinolones [8]. However, given the limitations of U.S. surveillance data, prospective clinical studies are needed to confirm the clinical significance of these findings, including whether rapid genotyping of isolates at the outset of treatment may benefit patient management.

Acknowledgments

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily represent an official position of the U.S. Centers for Disease Control and Prevention.

Author Contributions

Conceived and designed the experiments: CMY EVK JPC. Analyzed the data: CMY EVK ESC JSC. Wrote the paper: CMY EVK ESC JSC JPC.

References

1. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, et al. (2004) The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 39: 1321–1329.
2. Hanif M, Malik S, Dhingra VK (2009) Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int J Tuberc Lung Dis 13: 74–78.
3. Temple B, Ayakaka I, Ogwang S, Nabagia H, Kayes S, et al. (2008) Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 47: 1126–1134.
4. Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2: 10–11.
5. Chiang CY, Schaaf HS (2010) Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 14: 627–632.
6. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva: World Health Organization, Stop TB Department.
7. de Jong BC, Onipede A, Pym AS, Gagneux S, Aga RS, et al. (2005) Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol 43: 3530–3532.
8. Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328–337.
9. Gilson JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D (2002) Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 8: 843–849.
10. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis (2006) Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 12: 736–743.
11. Phyo P, Stavem R, Lwin T, Swehene OS, Ti T, et al. (2009) Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar. J Clin Microbiol 47: 335–344.
12. Malla B, Stucki D, Borell S, Feldmann J, Maharanjan B, et al. (2012) First insights into the phylogenetic diversity of Mycobacterium tuberculosis in Nepal. PLoS One 7: e52297.
13. Fyodorova, S, Godin B, Bovens B, Alpert E, Zouhalin M, et al. (2012) Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 3047–3053.
14. Click ES, Moonan PK, Winston CA, Cowan LS, Oelmann JE. (2012) Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 54: 211–219.
15. Kato-Maeda M, Gagneux S, Flores LL, Kim EY, Small PM, et al. (2011) Strain classification of Mycobacterium tuberculosis: congruence between large sequence polymorphisms and spoligotypes. Int J Tuberc Lung Dis 15: 131–133.

16. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, et al. (2006) Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 2069–2073.

17. CDC (2003) Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 52: 1–77.

18. Mitchison DA (2000) Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796-806.

19. Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7: 6–21.

20. Zhang Y, Pernar S, Sun Z (2002) Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51: 42–49.

21. Chedore P, Bertucci L, Wolf J, Sharma M, Jamieson F (2010) Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 48: 300–301.

22. Duong DA, Nguyen TH, Nguyen TN, Dai VH, Dang TM, et al. (2009) Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother 53: 4835–4839.

23. de Steenwinkel JE, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, et al. (2012) Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR. TB. Emerg Infect Dis 18: 660–663.

24. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, et al. (2013) Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45: 784–790.

25. Lew W, Pai M, Oxladde O, Martin D, Menzies D (2008) Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149: 123–134.

26. Lee SS, Meinjes G, Kamuruzaman A, Leung CC (2013) Management of tuberculosis and latent tuberculosis infection in HIV-infected persons. Respiratory.

27. Vernon A, Burman W, Benator D, Khan A, Bozeman L (1999) Acquired rifampin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353: 1843–1847.

28. Li J, Munnsill SS, Driver CR, Sackoff J (2003) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin Infect Dis 41: 83–91.

29. CDC (2012) Reported Tuberculosis in the United States, 2011. Atlanta, GA: Department of Health and Human Services, CDC.

30. World Health Organization (2006) Global Plan to Stop TB 2006–2015. Geneva: World Health Organization.

31. Pasipanodya JG, Gambo T (2013) A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis Patients. Clin Infect Dis 57: 21–31.

32. Erdova JV, Kurbatova EV, Moonan PK, Cegielski JP (2012) Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 55: 1600–1607.

33. Pasipanodya JG, McCullum H, Burger A, Wash PA, Smith P, et al. (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208: 1464–1473.

34. Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, et al. (2012) Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev 25: 708–719.

35. Jasmer RM, Beerbaum L, Schwartzman K, Cave MD, Saikkanen J, et al. (2004) Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 170: 1360–1366.

36. Hlavac MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, et al. (2008) Human tuberculosis due to Mycobacterium bovis in the United States, 1995–2005. Clin Infect Dis 47: 168–173.

37. World Health Organization (2006) Global tuberculosis control: WHO report. Geneva: Global Tuberculosis Programme.